Wolverine Trading’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-18,973
| Closed | -$959K | – | 5471 |
|
|
2020
Q2 | $649K | Buy |
+18,973
| New | +$555K | ﹤0.01% | 2456 |
|
|
2020
Q1 | – | Sell |
-18,282
| Closed | -$308K | – | 5628 |
|
|
2019
Q4 | $389K | Sell |
18,282
-33,537
| -65% | -$592K | ﹤0.01% | 3312 |
|
|
2019
Q3 | $742K | Buy |
51,819
+13,937
| +37% | +$205K | ﹤0.01% | 2227 |
|
|
2019
Q2 | $525K | Sell |
37,882
-10,578
| -22% | -$159K | ﹤0.01% | 2670 |
|
|
2019
Q1 | $931K | Sell |
48,460
-85,966
| -64% | -$1.39M | ﹤0.01% | 2149 |
|
|
2018
Q4 | $2.02M | Buy |
134,426
+31,849
| +31% | +$632K | 0.01% | 1405 |
|
|
2018
Q3 | $2.14M | Buy |
102,577
+52,994
| +107% | +$1.26M | ﹤0.01% | 1607 |
|
|
2018
Q2 | $724K | Hold |
49,583
| – | – | ﹤0.01% | 2607 |
|
|
2018
Q1 | $724K | Buy |
+49,583
| New | +$810K | ﹤0.01% | 2607 |
|
|
2016
Q3 | – | Sell |
-11,878
| Closed | -$33.2K | – | 5312 |
|
|
2016
Q2 | $27K | Buy |
+11,878
| New | +$39.7K | ﹤0.01% | 3881 |
|
Wolverine Trading's IMMU Position: Q3 2020 in Review
Wolverine Trading sold out of Immunomedics Inc (IMMU) in Q3 2020, closing a stake of 18,973 shares — an estimated $959K sold.
Wolverine Trading first reported a position in IMMU in Q2 2016 and held it in 10 quarters. The position peaked at $2.14M in Q3 2018. 408 funds tracked by Wall St. Rank hold IMMU as of Q3 2020.
- Wolverine Trading reported no remaining Immunomedics Inc position as of Q3 2020 after selling out during the quarter.
- Wolverine Trading sold 18,973 Immunomedics Inc shares in Q3 2020, an estimated $959K.
- Wolverine Trading first reported a position in Immunomedics Inc in Q2 2016 and held it in 10 quarters.
- Wolverine Trading's Immunomedics Inc position peaked at $2.14M in Q3 2018.
- 408 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2020.
Based on Wolverine Trading's 13F filing for Q3 2020, filed 13 Nov 2020.